|Bid||72.04 x 1100|
|Ask||72.14 x 1000|
|Day's Range||66.23 - 74.53|
|52 Week Range||15.52 - 95.21|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct. 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.54|
Brian Garibaldi, JHU Biocontainment Unit Director, joins The Final Round to discuss his thoughts on the rising numbers of cases across the globe and the most recent developments in the vaccine race.
As cases rise globally, Sanofi and GlaxoSmithKline have agreed to provide 20 million vaccine doses to the WHO’s COVAX program and the U.S. has agreed to pay $347 million for 300,000 doses of Eli Lilly’s antibody drug. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
Moderna's (NASDAQ: MRNA) primary focus right now is to hopefully win regulatory approvals or authorizations for coronavirus vaccine mRNA-1273 to make it to the market. Moderna reported revenue in the third quarter of $157.9 million, up a whopping 829% year over year. Perhaps the most important financial measure for Moderna was its cash position at the end of the third quarter.